Carcinoma of Urinary Tract

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2019-07-02
Clinical Trial Update: Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma [Phase 2]
Phase 2 trial evaluating ramucirumab or IMC-18F1 with docetaxel vs docetaxel alone as second-line therapy for urinary tract carcinomas, comp…